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Summary The cytotoxic activity profile of an immunotoxin, SWA 11 -ricin A chain, recognising a cell-surface
antigen associated with human small cell lung cancer (SCLC), was examined in detail using a panel of SCLC,
non-SCLC and non lung tumour cell lines in tissue culture. SWA 11 -ricin A chain was potently and selectively
active against three SCLC cell lines of both classic and variant morphologies, inhibiting the incorporation of
3H-leucine with an IC50 of 5 x 10-" M. At a concentration of 1 x 10-8 M, the SWAI immunotoxin could
selectively eliminate in excess of 99.9% of clonogenic tumour cells. Intoxication proceeded rapidly following a
4 h lag phase; the initial rate of protein synthesis inhibition occurred with a t% of 2 h and a t,o of 7 h. The
cytotoxic activity of SWA I-ricin A chain was potentiated by 100-fold in the presence of the carboxylic
ionophore monensin at
I x 10-7 M. Kinetic studies revealed that monensin enhanced the rate of protein
synthesis inhibition by two-fold and eliminated the lag phase suggesting a rapid effect on either the rate or
route of internalisation. Studies with SWA could detect no influence of monesin on the rate of antibody
internalisation and a transient delay in the delivery of internalised antibody to lysosomes was observed by
immunoelectron microscopy.
Human small cell lung cancer (SCLC) is an aggressive, highly
metastatic disease with poor prognosis (Minna et al., 1989).
The success of combined chemotherapy in treating SCLC at
presentation is counterbalanced by the short time to relapse
and poor long term patient survival (Beck et al., 1988). The
development of new approaches designed to augment or
replace the standard regimens is clearly a high priority.
Antibody-toxin conjugates, or immunotoxins (ITs) made
with the ribosome-inactivating protein ricin A chain have
been used for the treatment of patients with leukaemia,
lymphoma and metastatic solid tumours in clinical trials
(Cobb et al., 1991; Hertler & Frankel, 1991; Wawrzynczak,
1991). We have been investigating the potential role of ricin
A chain ITs in the systemic therapy of SCLC. The mouse
monoclonal antibody (Mab) SWA 11 recognises a 45 kDa cell
surface glycoprotein designated the cluster w4 antigen by the
First International Workshop on SCLC Antigens (Souhami
et al., 1988) which is highly expressed by SCLC and also
present on a proportion of leukocytes, proximal tubules of
kidney, bile ducts, bronchial glands and peripheral nerve. An
indirect assay of IT cytotoxicity found that SWA 11 mediated
the entry of ricin A chain into antigen-positive target cells
with concomitant intoxication (Wawrzynczak et al., 1990a,
1991b). Preliminary data from comparative experiments have
revealed SWAl 1-ricin A chain to be amongst the most
effective of a panel of ricin A chain ITs directed against the
five defined cell surface antigens most commonly associated
with SCLC and, therefore, a leading candidate for therapy of
SCLC (Wawrzynczak et al., 1991a).
The aim of the present study was to examine in detail the
cytotoxic effects of SWA 11-ricin A chain against a panel of
SCLC, non-small cell lung cancer (NSCLC) and non-lung
control tumour cell lines in tissue culture. We present evi-
dence of the selective cytotoxic action of SWA 11-ricin A
chain, demonstrate rapid kinetics of protein synthesis inhibi-
tion and a high efficacy of clonogenic cell kill, and show that
the carboxylic ionophore monensin is able to substantially
potentiate the activity of the IT.
Materials and methods
Reagents and media
'25I-iodide with a specific activity of 100 Ci ml-' was pur-
chased from ICN Biomedicals Ltd., High Wycombe, Bucks,
England. Iodogen was bought from Pierce & Warriner Ltd.,
Chester, England. L-[4,5-3H]leucine with a specific activity of
45-70 yLCi molh' and goat anti-mouse Ig antibody-5 nm gold
conjugate were purchased from Amersham International plc,
Amersham, Bucks, England. Papain was from Sigma Chemi-
cal Co. Ltd., Poole, Dorset, England. Sephacryl S200 (HR)
and Sephadex PD-10 G-25M columns were obtained from
Pharmacia Ltd., Milton Keynes, Bucks, England.
Foetal calf serum was purchased from Sera-Lab Ltd.,
Crawley Down, Sussex, England, and RPMI-1640 and leu-
cine-free RPMI-1640 were obtained from ICN Biomedical
Ltd., and Gibco Ltd. Paisley, Scotland, respectively.
Potentiating agents were purchased from Sigma Chemical
Co Ltd. Ammonium chloride-,#nd methylamine prepared at
1M, and verapamil and chloroquine at 1OmM in reagent
grade water were sterilised by filtrationland stored at - 2OC.
Monensin prepared at 0.1 M and perhexiline at 1OmM in
ethanol were stored at - 70°C, and were diluted at least
1,000-fold in medium in the cytotoxicity assays.
Preparation ofimmunotoxins
Ricin A chain was attached to the SWA 11 and 2AL-1 Mabs
(both mouse IgG2a) via a disulphide bond as described
previously (Wawrzynczak et al., 1990). Briefly, 2-pyridyl-
disulphide groups were introduced into the Mabs by reaction
with a 5-fold molar excess of N-succinimidyl 3-(2-pyridyl-
dithio)propionate (SPDP). The derivatised antibodies were
reacted overnight with a 2.5-fold molar excess of freshly
reduced ricin A chain. The reaction mixture was applied to a
column of Sephacryl S200 (HR) and fractions of eluate
containing predominantly conjugate consisting of one A
chain molecule attached to one Mab molecule were pooled.
The preparations also contained smaller amounts of more
highly substituted Mab and unconjugated Mab.
Cell lines
The human classic SCLC cell lines NCI-H69 (Carney et al.,
1985) and GLC-8 (Postmus et al., 1988) were provided by Dr
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L. Kelland at the Institute of Cancer Research, Sutton and
Dr L. de Leij at the University Hospital, Groningen, The
Netherlands, respectively. The human variant SCLC cell line
SW2 was a gift from Dr R. Stahel at the University Hospital,
Zurich, Switzerland. The human lung adenocarcinoma cell
lines NCI-H23 and NCI-H125 (Carney et al., 1985) were
provided by Dr V. Macaulay at the Institute of Cancer
Research, Sutton. The human T-lymphoblastoid cell line
CEM was obtained from the American Type Tissue Culture
Collection.
Cell lines were maintained in a humidified atmosphere of
5% CO2 in air at 37°C. The lines were cultured in RPMI-
1640 supplemented with 10% (v/v) heat-inactivated foetal
calf serum, 2 mm L-glutamine, 100 IU ml' penicillin, and
100 gmlg l streptomycin (growth medium). SCLC cells
growing as aggregates in suspension and adenocarcinoma
cells growing as monolayer cultures were disaggregated to
predominantly single cells for use in experiments as described
previously (Wawrzynczak et al., 1990). The T-lymphoblastoid
cell line CEM grew as a suspension of single cells in tissue
culture. Cell suspensions for cytotoxicity assays were
prepared in medium containing leucine-free RPMI-1640
(assay medium).
Cytotoxicity assays
3H-leucine incorporation assay Cytotoxicity experiments
with cell lines in tissue culture were conducted as described
previously (Wawrzynczak et al., 1990) with some modifica-
tions. Suspension cultures were adjusted to a density of
2 x I05 single cells ml-' in assay medium. Aliquots (0.1 ml)
of cell suspension were distributed into the wells of a 96-well
tissue culture plate and incubated at 37°C for 1-2 h. Samples
of IT or other agents were prepared in assay medium and
added to the wells in 0.1 ml aliquots. Control cultures con-
tained added assay medium only. Cultures were incubated in
the continuous presence of IT for 48 h at 37°C and were then
pulsed with 1 giCi of 3H-leucine for 4-24 h at 37°C depend-
ing on the cell line and its level of 3H-leucine incorporation.
Cells were then harvested onto filters using an automated cell
harvester. The incorporation of 3H-leucine was determined
by liquid scintillation counting of filters. In some experi-
ments, potentiating agents were included in both test and
control cultures.
Monolayer cultures of NSCLC cell lines were adjusted to a
density of 5 x 105 single cells ml-' in assay medium. Aliquots
(0.1 ml) of cell suspension were distributed into the wells of a
24-well tissue culture plate which contained 0.8 ml of assay
medium and were incubated overnight to allow the cells to
adhere to the plate. Samples of IT or other agents prepared
in assay medium were added in 0.1 ml aliquots to the cul-
tures which were incubated at 37°C for a further 48 h and
pulsed with 1 ,uCi of 3H-leucine for 4 h. The cells were
washed with PBS, fixed with 5% (w/v) tricholoroacetic acid,
washed with methanol and dried. The contents of each well
were solubilised by incubation with 0.2 ml of 1 M NaOH
solution for 1 h at 37°C. The incorporation of 3H-leucine was
determined by liquid scintillation counting of 0.15 ml samples
of the solubilised cells.
Kinetics ofprotein synthesis inhibition In assays to measure
the kinetics of protein synthesis inhibition, 0.1 ml samples of
SWA11-ricin A chain or ricin at a concentration of 2 x
10-8 M were mixed with 0.1 ml of a single cell suspension of
the SW2 SCLC cell line and incubated for various times at
37°C before pulsing with 5 gCi of 3H-leucine for 1 h at 37°C,
harvesting and counting of incorporated radioactivity as des-
cribed above.
Limiting dilution clonogenic assay Single cell suspensions of
the SW2 SCLC cell line 3.5 ml at a density of 2 x 105
cells ml-' in growth medium - were placed in 25 cm3 tissue
culture flasks and incubated at 37°C for 1-2 h. An equal
volume of SWAl1-ricin A chain, ricin A chain or ricin
solution, each at a concentration of 2 x 10-8 M in growth
medium, or growth medium alone (control), was added to
each flask and the cultures incubated for 48 h at 37°C. Cells
were then removed from the flasks into 30 ml sterile Univer-
sal containers and centrifuged at 1,000 r.p.m. for 5 min.
Supernatants were discarded and cells were gently resus-
pended in 0.7 ml of growth medium to provide the cell
suspensions for the limiting dilution assay.
The cell suspensions were then serially diluted 10-fold in
growth medium. From cell suspensions at each density, six
0.1 ml samples were added to 0.1 ml of growth medium in
the wells of a 96-well tissue culture plate and incubated at
37°C for 14 days. The clonogenic growth of surviving tumor
cells was evaluated using inverted phase microscopy to score
the number of wells that contained at least one colony. A
colony was defined as a coherent group of 30 or more cells
which were densely packed. The colony forming efficiency of
the untreated control cell cultures was 16%.
The number ofclonogenic units per well in the cell suspen-
sions were calculated by a modification of the Spearman
technique (Johnson & Brown, 1961) according to the for-
mulae:
Clonogenic units/well = e-057722 -A
where A = In (5 x 10-2) + InlO/2 -InlO(s)/6
and s = sum of the wells in which at least one colony was
observed from cells at dilutions of 5 x 10-2 to 5 x 10-7
relative to the starting cell suspensions.
Internalisation ofSWA1I Mab
Radiolabelled Mab The monoclonal antibody SWAl1 was
radioiodinated using the method of Fraker and Speck (1978)
to a specific activity of 1.3 mCi mg-'. A single cell suspension
of SW2 cells at a density of 1 x 107 cells ml1l was mixed with
an equal volume of 125I-SWA 1I at a concentration of 2 x
108 M in assay medium and was incubated on ice for 1 h to
allow binding of the Mab to the cell surface. The treated cells
were then washed three times with ice-cold PBS by repeated
centrifugation (1,000 r.p.m. for 5 min at 8°C) and resuspen-
sion to remove unbound Mab. The cells were finally resus-
pended at a density of approximately 5 x 105 cellsml-I in
assay medium alone or in assay medium containing monen-
sin at a final concentration of 1 x 10- M. Following incuba-
tion for various lengths of time at 37°C, the cultures were
washed twice with ice-cold PBS. To determine the proportion
of internalised '25I-SWAI1, cell pellets in triplicate were
resuspended in either 50,l of papain solution (5 Uml- in
20 mM cysteine solution) to remove cell surface-bound radio-
activity, or in 50ga of PBS to determine total cell-associated
radioactivity. The cells were incubated on ice for 30min,
washed twice with 0.2 ml of ice-cold PBS and the associated
radioactivity in each case was measured in a gamma counter.
Immunoelectron microscopy
SW2 cells at a density of 2.5 x 107 cellsml- were incubated
with the SWA11 Mab at a final concentration of 2 x 10-6 M
in assay medium on ice on a rocking platform for 1 h. Cells
were washed three times in ice-cold PBS by repeated centri-
fugation (1,000 r.p.m. for 5 min at 80C) and resuspension.
Cells pellets were then resuspended in ice-cold medium con-
taining goat anti-mouse Ig antibody-5 nm gold conjugate
diluted 40-fold and incubated on ice for a further 1 h. The
cells were washed three times in ice-cold PBS to remove
unbound gold conjugate. Following the final wash, the cell
pellets were resuspended in assay medium at a density of
approximately 5 x 105ml' either in the presence or absence
of monensin at a final concentration of 1 x 10-7M. The
antibody-treated cells were incubated for various periods of
time at 37°C and then centrifuged at 1,000 r.p.m. for 5 min at
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Cell pellets were prepared for immunoelectron microscopy
essentially as described previously (Monaghan et al., 1985).
Briefly, samples were fixed in 2% (v/v) glutaraldehyde in
50 mM sodium phosphate buffer containing 1.7% (w/v) suc-
rose overnight and post-fixed in 1% (w/v) osmium tetroxide
solution in 50 mM sodium phosphate buffer containing 8.6%
(w/v) sucrose for 2 h. Samples were dehydrated in ethanol,
transferred to propylene oxide, and embedded in Epon:Aral-
dite. Sections (100 nm thick) were cut with a diamond knife
using a Reichert-Jung Ultracut microtome and examined
without contrasting on a Philips CM10 Transmission Elec-
tron Microscope at 60 kV.
For each batch of cells, the number of gold particles was
counted on randomly chosen sections passing through the
nucleus of ten different cells. The gold particles were separ-
ately counted on the plasma membrane, in endosomes
(vesicles with a clear matrix) and lysosomes (vesicles with a
dense matrix), and vacuolar compartments of abnormal mor-
phology resulting from monensin treatment.
Results
Cytotoxic effects ofSWAII-ricin A chain against apanel of
tumour cell lines
The ability of SWA 11-ricin A chain to exert toxic effects
against SCLC, NSCLC and a control human non-lung
tumour cell line was tested in tissue culture in parallel with
an isotype-matched control IT of irrelevant specificity, 2AL-
1-ricin A chain, with unconjugated ricin A chain, and with
ricin using a 'H-leucine incorporation assay (Table I).
SWA1 1-ricin A chain was potently toxic to the three
SCLC cell lines, SW2, NCI-H69 and GLC-8, inhibiting the
incorporation of 3H-leucine by 50% at a concentration (IC50)
ranging between 3.7 x O-0` M and 5.2 x 1O-" M. At a con-
centration of 1 x 10-8 M, SWAI1-ricin A chain reduced 3H-
leucine incorporation into all three SCLC cell lines by greater
than 98%. In contrast, the IC50 values of 2AL-1-ricin A
chain and unconjugated ricin A chain were greater than
1 X 10-8 M against the SCLC cell lines examined. The sen-
sitivity of the SCLC lines to ricin varied over a 20-fold range
with IC,Os between 2.9 x 10-3 M and 4.5 x 10-12 M.
SWA1 1-ricin A chain was about 50- to 100-fold less active
against the lung adenocarcinoma cell line NCI-H125 (IC50,
2.5 x 109 M) and had no selective activity against the lung
adenocarcinoma cell line NCI-H23 although both cell lines
were sensitive to ricin toxin. The lower potency of the
SWA 11 IT against the NSCLC cell lines reflects a lower
expression of the cluster w4 antigen as judged by indirect
immunofluorescence.
The human T-lymphoblastoid cell line CEM, which did
not detectably bind the SWA 11 Mab as judged by indirect
immunofluorescence and flow cytometric analysis, but which
was sensitive to ricin intoxication, was used as a control
non-lung tumour cell line. SWA 11-ricin A chain at concen-
trations as high as 1 X 10-7 M had no significant inhibitory
effect on this cell line demonstrating the necessity of surface
expression of the cluster w4 antigen for sensitivity to the
action of the IT.
Specificity ofSWAII-ricin A chain action against the SW2
SCLC cell line
The specificity of action of SWAl 1 -ricin A chain was
examined in detail using the SW2 cell line in tissue culture.
Figure la shows a representative concentration-activity
curve.
SWAl 1-ricin A chain acted in a concentration-dependent
fashion reducing 3H-leucine incorporation to less than 2% of
control cultures at concentrations as low as 1 x 10- M. In
contrast, unconjugated A chain, unconjugated SWA 1, or
the isotype-matched control ricin A chain IT, had no signi-
ficant effect at equivalent concentrations. The SWA 11 IT was
about 1,000-fold more potent than unconjugated ricin A
chain or the control IT as judged from IC50 values.
Unconjugated SWAl was able to inhibit the cytotoxic
action of the SWAl 1 IT (Figure Ib). Inclusion of SWAl 1 at
1 X 10-7 M in the cytotoxicity assay increased the IC,o by
about 50-fold, from about 2 x 10- M to x 10-9 M. In a
parallel experiment, the irrelevant IgG2a Mab, 2AL-1, at
1 X 10-7 M had no effect on the cytotoxic activity of the
SWA1 1 IT.
Taken together, these results demonstrate that the selective
cytotoxic action of the SWAI1 IT was dependent upon
binding of the intact ricin A chain conjugate to the cell
surface via the antigen combining sites of the Mab compo-
nent.
Kinetics ofprotein synthesis inhibition ofSWAII-ricin A chain
The kinetics of protein synthesis inhibition by SWAlI-ricin
A chain and ricin were determined by incubating SW2 cells
in the continuous presence of the IT or toxin at a concentra-
tion of 1 x 108 M and measuring the effect of 3H-leucine
incorporation.
Ricin intoxication proceeded extremely rapidly: protein
synthesis was reduced by 50% in a time (t50) of 0.5 h and by
one order of magnitude in a time (t,0) of about 2 h. No
appreciable lag phase was evident. In contrast, SWAll-ricin
A chain did not significantly affect protein synthesis until
after 4 h of incubation. Following this lag phase, the initial
rate of protein synthesis inhibition was relatively rapid with a
t50 of about 2 h and a t1o of about 7 h.
Effect ofSWAII-ricin A chain on the clonogenic growth ofthe
SW2 cell line
SW2 cells were exposed to SWAll-ricin A chain, ricin A
chain or ricin at a concentration of 1 x 1O-8IM for 48 h
under conditions resembling the 3H-leucine incorporation
assay, and estimates of surviving clonogenic units were made
Table I Cytotoxic effects ofSWA11-ricin A chain, 2AL-l-ricin A chain, ricin A chain,
and ricin against human tumour cell lines in tissue culture
Agent IC50a (M)
(A) SW2 NCI-H69 GLC-8
SWAll-ricinAchain 3.7±2.1 x 10-"1 3.8±2.4x 10-" 5.2±4.2x 10-
2AL-l-ricin A chain 1.6±0.8 x 10-8 2.5± 1.5 x 10-8 4.2± 2.1 x 10-8
Ricin A chain 3.2±0.2 x 10-8 2.6±0.4 x 10-8 5.8± 2.3 x 10-8
Ricin 2.9±1.7 x 10-13 7.9±3.2x 10-13 4.5±0.1 x 10-'2
(B) NCI-H125 NCI-H23 CEM
SWA ll-ricin A chain 2.5±1.4 x 10-9 > 1.0 x 10-8 > 1.OX l0-7
2AL-l-ricin A chain > 1.0 x 10-8 > 1.0 x 10-8 > 1.0 x 10-8
RicinAchain >1.0x 10-8 >1.0x 10-8 >1.0x 10-8
Ricin 5.1±0.9 x 10-13 6.3± 1.8 x 10-3 1.4±0.2x 10-x 2
(A) SCLCcell lines. (B)Other tumourcell lines. aTheIC50sasquoted arethemeanvalue
and standard deviation from the mean derived from at least three independent
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by a limiting dilution assay. Table II presents the results of
an assay representative of two independent experiments
which gave equivalent results. The cytotoxic activities of
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Figure 1 Toxic effects of SWA 1 -ricin A chain and other agents
against the human SCLC cell line SW2 in tissue culture. a, SW2
cells were incubated for 48 h in the continuous presence of
SWAlI-ricin A chain (0). 2AL-l-ricin A chain (A), SWAl1
(0), ricin A chain (A), or ricin (-) at the concentrations shown,
and for a further 4 h in the presence of 3H-leucine. b, SW2 cells
were incubated for 48 h in the presence of SWAl 1-ricin A chain
at the concentrations shown, either alone (A) or in combination
with SWAl (O) or with 2AL-1 (0), each at a concentration of
I x l0-7 M, and then for a further 4 h in the presence of 3H-
leucine. The results are expressed as the incorporation of 3H-
leucine as a percentage of untreated control cultures. The mean
values of quadruplicate a or triplicate b determinations are
shown. The error bars denote the standard deviations from the
mean values unless smaller than the symbols shown.
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Figure 2 Kinetics of protein synthesis inhibition by SWA 1-ricin
A chain. SW2 cells were incubated in the continuous presence of
IT (0) or ricin (U) at a concentration of 1 x 10-8 M for the
stated times and then for a further 1 h in the presence of 3H-
leucine. The results are expressed as the mean and standard
deviation of quadruplicate determinations of 3H-leucine incor-
poration as a percentage of untreated controls.
Table II Effects ofSWAl l-ricin A chain, ricin A chain and ricin on
colony formation by the SW2 SCLC cell line in tissue culture
Number ofwells containing colonies
Dilution Control Ricin SWAIJ-ricin A Ricin A chain
5 x 10-' 6/6 0/6 0/6 6/6
5 x 10-2 6/6 0/6 3/6 6/6
5 x10-3 6/6 0/6 0/6 6/6
5 x 10-4 6/6 0/6 0/6 6/6
5 x l0-5 6/6 0/6 0/6 6/6
5 x 10-6 2/6 0/6 0/6 0/6
5 x 10-7 0/6 0/6 0/6 0/6
Surviving
clonogenic
units per ml 3.78 x 105 <5 56 1.76 x 105
Inhibition (% 0 >99.999 99.985 54.439
ofcontrol)
SWAll-ricin A chain, unconjugated ricin A chain and ricin
were judged from the reduction in the number of colonies
evident at different cell densities compared with the untreated
control cell culture. SWA11-ricin A chain reduced the surviv-
ing fraction ofclonogenic SW2 cells by 99.985%, close to the
limit of detection of the assay whereas unconjugated ricin A
chain inhibited the clonogenic growth of SW2 cells by only
about 50%.
In the case of cells treated with SWAlI-ricin A chain,
colonies were only seen to occur, singly, in half of the wells
containing the 5 x 10-2 dilution of cells. Surprisingly, col-
onies could not be identified in the 5 x 10-' dilution of
SWAI1I-ricin A chain treated cells. Although clumps of
about 30 cells were observed, some of which excluded trypan
blue, the cells adhered to one another as loose strings of cells
rather than appearing as coherent colonies. In the case of
ricin-treated cells, colonies could not be detected at any
dilution and the majority of cells observed were non-viable.
Potentiation ofSWAII-ricin A chain cytotoxicity by monensin
The ability of a panel of established potentiating agents to
enhance the cytotoxic activity of SWAI1I-ricin A chain
against the SW2 cell line was determined in tissue culture
using the 3H-leucine inhibition assay.
SW2 cells were incubated with each potentiator at a range
of concentrations either in the presence or absence of
SWAl 1-ricin A chain at a final concentration of 1 x 10-12 M,
the highest concentration of the IT which had no inhibitory
effect upon 3H-leucine incorporation. The lysosomotropic
amines - ammonium chloride, methylamine and chloroquine
- and the calcium antagonists - verapamil and perhexiline -
had little or no potentiating effect on SWAlI-ricin A chain
activity (not shown). In contrast, in combination with mone-
nsin at a concentration of 1 x IO-7 M, the SWA 11 IT inhib-
ited 3H-leucine incorporation by greater than 90% (Figure 3).
In the 3H-leucine incorporation assay, monensin enhanced
the cytotoxic activity of SWAl1I-ricin A chain by about
100-fold reducing the IC50 to 2.4 x I0-`3 M, equivalent to the
potency of ricin in the absence of potentiator (Figure 4a). A
similar degree of activity enhancement was observed when
SW2 cells, which had been pre-treated with SWAlI-ricin A
chain for 1 h on ice and then washed to remove unbound IT,
were incubated in the presence of monensin (not shown).
This result indicated that the effect of the ionophore occurred
after attachment of the IT to the cell surface. Monensin
altered the kinetics of protein synthesis inhibition by SWA 1-
ricin A chain in two ways (Figure 4b). Firstly, co-incubation
of SWAll-ricin A chain with monensin eliminated the 4 h
lag phase detected in the absence of ionophore. Secondly,
monensin enhanced the rate of protein synthesis inhibition
reducing the t5o to about 1 h and the t1o to about 3 h.
The potentiating effect of monensin on IT activity was not
entirely selective although the cytotoxic activities of ricin and
ricin A chain were enhanced by only 8- and 10-fold respec-
tively in a parallel experiment (not shown).448 E.J. DERBYSHIRE et al.
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Figure 3 Enhancement of SWAI l-ricin A chain activity by
potentiating agents. SW2 cells were incubated for 48 h either in
the presence of monensin alone (0) or in the presence of
SWAl l-ricin A chain at a concentration of 1 x 10-12 M (@), and
then for a further 4 h in the presence of 3H-leucine. The results
are expressed as the incorporation of 3H-leucine as a percentage
of untreated control cultures. The mean values of duplicate deter-
minations are shown.
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Influence ofmonensin on the rate ofSWAII Mab
internalisation by SW2 cells
The effect of monensin upon the rate of internalisation of the
SWA Il Mab into SW2 cells was studied using cells which
had been incubated with '25I-SWA 1I on ice for 1 h. The
labelled cells were warmed to 37°C in the presence or absence
of the potentiator before washing the cells to remove any
dissociated 1251I-SWA1 1. The total cell-associated radioactivity
was measured after various times of incubation. In addition,
the amount of internalised Mab was estimated by removing
'251I-SWA11 present at the cell surface by a papain treatment
which had been shown to remove greater than 95% of cell
surface-bound radioactivity in trial experiments.
In the absence of monensin, the incubation of '25I-SWA11-
treated cells at 37°C resulted in a gradual increase in the
papain-resistant fraction over the first 8 h, indicating that
bound 1251I-SWAI 1 had become internalised to a papain-
resistant compartment of the cell (Figure 5a). After 8 h, the
papain-resistant fraction represented about 25% of the radio-
activity originally bound to the cells and about 50% of the
remaining cell-associated radioactivity. After 24 h of incuba-
tion at 37°C, there was minimal papain-resistant radioactivity
suggesting that '251I-SWA11 had been degraded and free
radionuclide had been released from the cells. No significant
difference in the rate of 125I-SWAII internalisation could be
detected in the presence or absence of monensin. In addition,
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Figure 4 Toxic effects of SWAIl-ricin A chain in combination
with the carboxylic ionophore monensin. a, SW2 cell were incu-
bated for 48 h with SWAI1-ricin A chain in the presence (0) or
absence (0) of monensin at a concentration of 1 x 10-7 M, and
for a further 4 h in the presence of 3H-leucine. b, SW2 cells were
incubated in the presence of SWA 1 -ricin A chain at a concentra-
tion of 1 x 10-8 M in the presence (-) or absence (0) of monen-
sin at a concentration of 1 x 10-7 M for the times indicated, and
were pulsed with 3H-leucine for 1 h. The results were calculated
as a percentage of the 3H-leucine incorporated by relevant control
cultures with or without monensin. The mean values and stan-
dard deviations of triplicate a or quadruplicate b determinations
are shown.
Figure 5 Rate of internalisation of SWAI 1 into SW2 cells in the
presence and absence of monensin. a, SW2 cells, pre-incubated
with 125I-SWAI1, were incubated for the times shown either in
the presence of monensin at a concentration of 1 x 10-' M (filled
symbols) or in its absence (open symbols). Cells were then either
incubated in the presence of papain (squares) to determine the
papain-resistant fraction of the total cell-associated radioactivity
(circles). The mean values and standard deviations of triplicate
determinations are shown. b, SW2 cells, pre-incubated with
SWA11 and anti-mouse Ig antibody-gold conjugate, were incub-
ated for the times indicated in the presence (filled symbols) or
absence (open symbols) of monensin at a concentration of 1 x
10-7 M and then processed for electron microscopy. Ten cell
sections in each case were examined to determine the number of
internalised gold particles (squares) and the total number of
cell-associated gold particles (circles).
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the total cell-associated radioactivity in monensin-treated and
untreated cells was similar at each time point.
Control experiments determined that binding of '251-
SWAl to SW2 cells could be competed by inclusion of
unlabelled SWAl but not by the control Mab 2AL-1, and
that 125I-SWA1 1 did not associate in significant amounts with
the target antigen-negative cell line CEM (not shown).
Influence ofmonensin on the rate and route ofSWAII Mab
internalisation by indirect immunoelectron microscopy
The route of SWA 11 internalisation by SW2 cells was
examined by indirect immunoelectron microscopy. SW2 cells
labelled with SWAl 1 and a goat anti-mouse Ig antibody-gold
conjugate were incubated at 37°C for various times in the
presence and absence of monensin. Cell sections were viewed
by transmission electron microscopy to assess the total
number of cell-associated gold particles and the proportion
and distribution of internalised gold particles.
Prior to warming the cells, gold particles were located
exclusively at the cell surface (Figure 6a). Although the cells
were incubated with a relatively high concentration of
SWA 11 and then with anti-mouse Ig antibody-5 nm con-
jugate in excess, only low densities of gold particles were
observed on SW2 cells (26 to 87 gold particles per cell profile
at the start of incubation) in several experiments. The labell-
ing was specific because no gold particles were observed in 10
cell profiles when SW2 cells were treated with the control
2AL-1 Mab instead of SWAI 1.
The number of gold particles present within intracellular
compartments increased with time of incubation at 37°C and
was unaffected by the inclusion of monensin in the incuba-
tion medium (Figure 5b). After 2h, gold particles were
detected in lysosomes (Figure 6b). By 8 h, about 15% of the
gold originally bound at the cell surface was located intracel-
lularly. The amount of intracellular gold continued to in-
crease with time and, after 24 h, about 20% of gold was
located intracellularly. At this time, it was difficult to discern
individual gold particles since they were generally found
clumped within lysosomes (Figure 6c). This suggests that the
gold label was no longer associated with SWA 11 consistent
with degradation of the Mab. The levels of total cell-assoc-
iated gold label declined in monesin-treated and untreated
cells at a similar rate, and at a rate similar to the decline of
cell-associated radioactivity in the '25I-SWAl study.
To examine the possibility that monensin altered the intra-
cellular routing of SWAl 1, the distribution of the internal-
ised gold label was analysed by counting the number of gold
particles associated with endosomes, lysosomes, or vacuolar
compartments of abnormal morphology resulting from
monensin treatment, at each time point. Only low numbers
of gold particles were found in endosomes and at no time
was there a significant difference between monensin-treated
and untreated cells (not shown). The distribution of gold
particles within lysosomes was generally similar throughout
the time-course of the experiment. The single exception was
the failure to detect any particles whatsoever in the lysosomes
of cells which had been treated with monensin for only 1 h.
This finding suggests that the ionophore may have had an
early effect on intracellular routing (Table III). The appear-
ance of an occasional gold particle within vesicles of abnor-
mal morphology (Figure 6d) was noted only after 8 h of
incubation in the presence of monensin.
Discussion
The purpose of the present study was to examine in detail the
cytotoxic action of the anti-SCLC IT SWAl l-ricin A chain.
The major findings were: (i) SWAl 1-ricin A chain con-
sistently exerted potent cytotoxic effects against SCLC cell
lines, (ii) the toxic action of the IT was selective for tumour
cell lines expressing the target antigen, (iii) the most potent
cytotoxic effects were against SCLC cell lines, (iv) cell intox-
ication by the IT was characterised by a lag phase followed
a
C
Figure 6 Immunoelectron microscopy of SWAI1 internalisation
by the SW2 cell line, a, Surface-bound antibody at the start of
incubation. b, Gold particles within lysosomes after 2 h of incu-
bation, untreated cells. c, Clumped gold particles present within
lysosomes at 24 h, untreated cells. d, Antibody within vesicles of
abnormal morphology in monensin-treated cells following 24 h of
incubation. The bar line indicates a length of 0.1 gim.
by rapid kinetics of protein synthesis inhibition, (v) expres-
sion of the target antigen on a high proportion of SCLC cells
ensured a high percentage elimination of clonogenic tumor
cells, (vi) the activity of the IT was selectively enhanced by
the carboxylic ionophore monensin but not by other poten-
tiating agents, (vii) monensin accelerated the onset, and in-
creased the rate, of protein synthesis inhibition, and (viii)
monensin had no detectable influence on the rate of entry of
theSWAu 1 Mab but may have transiently delayed transfer
of the Mab to lysosomes.
The present study has conclusively demonstrated that the
most important activity criteria demanded of a therapeutic
IT are fulfilled by SWAll-ricin A chain. Firstly, SWAl1-
ricin A chain was highly active towards all the SCLC cell
lines examined: against the three SCLC cell lines, which were
of both classic and variant morphologies, the IT exerted
similar potent cytotoxic effects. The comparable susceptibility
of the SCLC cell lines reflects the high frequency of expres-
sion of the cluster w4 antigen both on SCLC tumours and
cell lines (Souhami et al., 1988) and suggests that a high450 E.J. DERBYSHIRE et al.
Table III Localisation ofgold particles within lysosomes ofthe SW2
cell line treated with SWAI1 in the presence or absence ofmonensin
Number ofcell sectionsa
Time (h) ob 1-5 6-10 >10
1_c 4 6 0 0
1+ 10 0 0 0
2- 4 5 1 0
2+ 5 4 0 1
4- 4 4 0 2
4+ 5 4 1 0
8- 5 2 1 2
8+ 3 2 4 1
24- 1 3 1 4
24+ 2 3 0 5
aNumber of cell sections containing the given numbers of gold
particles from ten cell sections examined in each case. bNumber of
lysosomal gold particles identified within a single cell section. C-/+
monensin at a concentration of 1 x 10-7 M.
proportion of the target patient population with SCLC will
have IT-sensitive disease.
Secondly, the cytotoxic action of the IT was selective for
cluster w4 antigen-positive cell lines. The dependence of the
anti-tumour activity of SWAI1-ricin A chain upon binding
to the cluster w4 antigen was demonstrated by three findings:
(i) lack of any selective effect of an isotype-matched control
IT of irrelevant specificity, (ii) inhibition of IT action by
excess unconjugated SWAl1 Mab, and (iii) lack of action of
the IT on an antigen-negative tumour cell line at high con-
centration. The high activity of SWAl 1-ricin A chain against
the SCLC cell lines in particular, which probably reflects the
high level of expression of the target antigen on these lines
compared with other tumour cell lines, suggests a potential
therapeutic advantage in targeting SCLC.
Thirdly, the cytotoxic potency of the IT against SCLC is
sufficient to allow potentially tumouricidal doses to be
achieved in patients. Judging by the consistent IC50 values
determined for the SCLC cell lines, the potency of SWAl1-
ricin A chain exceeds that of ricin A chain ITs which have
previously been used for clinical trials of IT therapy in other
human solid tumours (Bjorn et al., 1985; Embleton et al.,
1986; Spitler, 1987). The sensitivity of SCLC cell lines to the
SWA 11 IT in tissue culture is likely to be a good indication
of the intrinsic susceptibility of SCLC tumours to the IT in
patients because SCLC cell lines generally retain the bio-
chemical and morphological characteristics of the tumours
from which they are derived (Klein et al., 1987; Vescio et al.,
1990; Tsai et al., 1990).
Fourthly, the intoxication of SCLC cells by the IT occur-
red rapidly. The kinetics of protein synthesis inhibition were
only some 3- to 4-fold slower than those of ricin toxin at
equivalent concentration. Rapid intoxication of target cells is
an important property of a therapeutic IT if escape of clono-
genic tumour cells from the action of IT by cell division is to
be minimised. The onset ofeffects upon protein synthesis was
delayed by 4 h from the time of first exposure of the cells to
IT. This lag presumably reflects the time required for the IT
to bind to the cell surface, to be internalised and to become
transported to the intracellular compartment involved with
the translocation of the A chain to the cytosol.
Fifthly, SWAl1-ricin A chain could selectively eliminate a
high proportion of colony-forming SCLC cells. The expres-
sion of the target antigen on a high proportion of tumour
cells is an important criterion for employment of ITs in
cancer therapy because these agents rely on binding to target
antigen-positive cells for their selective toxic action. The
ability of the IT to eliminate in excess of 99.9% clonogenic
tumour cells selectively suggests that a substantial effect on
tumour growth could be achieved.
A number of agents such as lysosomotropic amines, car-
boxylic ionophores or calcium antagonists, have previously
been shown to enhance the activity of ricin A chain ITs
(Casellas & Jansen, 1988). Only the ionophore monensin was
found to be capable of substantially potentiating the activity
of SWAl1-ricin A chain against the SW2 SCLC cell line. At
a concentration of 1 x 10-7 M, monensin decreased the IC50
of the IT by 100-fold giving a potency of action comparable
with that of ricin in the absence of ionophore. The effect of
monensin was apparently exerted at an early stage following
binding to the cell surface. Kinetic studies revealed that
monensin not only enhanced the rate of protein synthesis
inhibition but also eliminated the 4 h lag phase suggesting
that either the rate or the route of IT internalisation had
been rapidly affected. Studies with the SWAI 1 Mab could
detect no influence of monensin on the rate of antibody
internalisation. The only effect of ionophore detected on the
route of internalisation was an apparently transient delay in
the delivery of Mab to lysosomes consistent with the rapid
effects seen on IT kinetics. In general, the findings of the
present study correspond with those of previous studies
which analysed the effects of monensin on different ITs and
cellular targets (Casellas et al., 1984; Carriere et al., 1985;
Manske et al., 1986; Griffin et al., 1987). It is likely that
methods of enhancing IT activity using monensin in vivo
(Hertler et al., 1989; Colombatti et al., 1990; Griffin & Raso,
1991) would also be applicable to SWAlI-ricin A chain.
In conclusion, SWAlI-ricin A chain is rapidly, potently
and selectively toxic to a high proportion of SCLC tumour
cells in tissue culture. These favourable properties suggest
that the IT should be active against SCLC in vivo. Although
high activity in vitro is no guarantee of good activity in vivo,
it is nevertheless an obligatory requirement of an effective
cytotoxic agent. The ability of monensin to selectively in-
crease the potency of SWAl 1-ricin A chain after only a short
duration of exposure suggests that potentiation of the IT in
vivo might also be feasible. Experiments to determine the
anti-tumour efficacy of an SWAl l-ricin A chain IT designed
for therapy have been undertaken in a nude mouse SCLC
solid tumour xenograft model.
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